Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.08
-0.18-5.52%
At close: Jun 5, 5:00 PM EST
$3.06
-0.0191-0.62%
After Hours: Jun 5, 4:05 PM EST
BriaCell Therapeutics Corp Analyst Ratings
BCTXNASDAQ
BriaCell Therapeutics Analyst Ratings and Price Targets | NASDAQ:BCTX | Benzinga
BriaCell Therapeutics Corp has a consensus price target of $40 based on the ratings of 1 analysts. The high is $40 issued by HC Wainwright & Co. on August 27, 2025. The low is $40 issued by HC Wainwright & Co. on August 27, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on August 27, 2025, April 22, 2025, and February 3, 2025, respectively. With an average price target of $34.67 between HC Wainwright & Co., there's an implied 1032.56% upside for BriaCell Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for BriaCell Therapeutics
Loading calendar...
FAQ
What is the target price for BriaCell Therapeutics (BCTX) stock?
The latest price target for BriaCell Therapeutics (NASDAQ:BCTX) was reported by HC Wainwright & Co. on August 27, 2025. The analyst firm set a price target for $40.00 expecting BCTX to rise to within 12 months (a possible 1206.81% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?
The latest analyst rating for BriaCell Therapeutics (NASDAQ:BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics maintained their buy rating.
When was the last upgrade for BriaCell Therapeutics (BCTX)?
There is no last upgrade for BriaCell Therapeutics
When was the last downgrade for BriaCell Therapeutics (BCTX)?
There is no last downgrade for BriaCell Therapeutics.
When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on August 27, 2025 so you should expect the next rating to be made available sometime around August 27, 2026.
Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a maintained with a price target of $32.00 to $40.00. The current price BriaCell Therapeutics (BCTX) is trading at is $3.06, which is out of the analyst’s predicted range.
